Holen Sie sich die Stockscreener-App
0.7822
1.77%
-0.0141
Handel nachbörslich:
.81
0.0278
+3.55%
Schlusskurs vom Vortag:
$0.7963
Offen:
$0.79
24-Stunden-Volumen:
1.13M
Relative Volume:
1.14
Marktkapitalisierung:
$164.98M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-274.18M
KGV:
-0.3086
EPS:
-2.5346
Netto-Cashflow:
$-198.33M
1W Leistung:
-3.18%
1M Leistung:
+4.59%
6M Leistung:
-60.29%
1J Leistung:
-92.02%
1-Tages-Spanne:
$0.771
$0.8349
1-Wochen-Bereich:
$0.7158
$0.8483
52-Wochen-Spanne:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
490 ARSENAL WAY, SUITE 200, WATERTOWN
Vergleichen Sie NMRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
0.7822 | 164.98M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by California State Teachers Retirement System - Defense World
72,622 Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Shareholders Filed a Lawsuit Against Neumora Therapeutics for Misleading Drug Trial Claims - TradingView
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of “Hold” by Analysts - Defense World
Ameriprise Financial Inc. Takes Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics Holds Annual Stockholders Meeting - TipRanks
BNP Paribas Financial Markets Invests $221,000 in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Deutsche Bank AG Has $775,000 Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Kuehn Law Encourages Investors of Grocery Outlet Holding Corp. to Contact Law Firm - GlobeNewswire Inc.
26,500 Shares in Neumora Therapeutics, Inc. (NASDAQ:NMRA) Bought by Janus Henderson Group PLC - Defense World
Neumora Therapeutics’s SWOT analysis: navigating challenges in neuropsychiatric drug development - Investing.com India
Undervalued Opportunities: 3 Penny Stocks With Market Caps Above $30M - simplywall.st
Softbank Group CORP. Sells 1,005,726 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Price T Rowe Associates Inc. MD Cuts Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Purchased by Northern Trust Corp - Defense World
Orbimed Advisors LLC Has $8.53 Million Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics (NASDAQ:NMRA) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
HC Wainwright Has Pessimistic Outlook of NMRA Q2 Earnings - MarketBeat
Neumora Therapeutics faces Nasdaq delisting risk - Investing.com Australia
The Manufacturers Life Insurance Company Has $478,000 Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Releases Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Neumora Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com India
Neumora Therapeutics Faces Nasdaq Non-Compliance Notice - TipRanks
Neumora Therapeutics Inc On May 14, Receives Nasdaq Non-Compliance Notice - marketscreener.com
What is HC Wainwright’s Forecast for NMRA Q2 Earnings? - Defense World
William Blair Analysts Increase Earnings Estimates for NMRA - Defense World
Neumora Therapeutics’ Earnings Call: Progress Amid Challenges - TipRanks
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Sold by Price T Rowe Associates Inc. MD - Defense World
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm - The Malaysian Reserve
RBC Capital Sticks to Its Hold Rating for Neumora Therapeutics, Inc. (NMRA) - The Globe and Mail
Neumora Therapeutics, Inc.: Strengthened Financial Position and Strategic Operational Enhancements Drive Buy Rating - TipRanks
Neumora Therapeutics Venture Debt Facility - Leerink Partners
Neumora Therapeutics (NMRA) Retains Buy Rating with Stable Price Target | NMRA Stock News - GuruFocus
Strategic Developments and Long-Term Growth Prospects for Neumora Therapeutics Amid Financial Stability Enhancements - TipRanks
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Neumora Therapeutics Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Neumora Therapeutics Q1 2025 Sees Net Loss, Stock Rises - Investing.com
Neumora Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Transcript : Neumora Therapeutics, Inc., Q1 2025 Earnings Call, May 12, 2025 - marketscreener.com
Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely? - Yahoo Finance
Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire
Neumora Therapeutics (NMRA) Expected to Announce Earnings on Monday - Defense World
Neumora Therapeutics Inc (NASDAQ: NMRA): What Matters Now - Stocksregister
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of "Hold" by Analysts - MarketBeat
Schonfeld Strategic Advisors LLC Buys 381,676 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Hold” by Analysts - Defense World
Investigation announced for Long-Term Investors in shares - openPR.com
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neumora Therapeutics Inc-Aktie (NMRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
| Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
| Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
| Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
| Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):